AW
ABBV icon

Alaethes Wealth’s AbbVie ABBV Stock Holding History

Alaethes Wealth’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.75M Buy
10,922
+1,173
+12% +$252K 0.8% 36
2026
Q1 		$2.12M Sell
9,749
-152
-2% -$33.7K 0.6% 51
2025
Q4 		$2.26M Sell
9,901
-141
-1% -$32.1K 0.64% 48
2025
Q3 		$2.33M Sell
10,042
-262
-3% -$53.4K 0.66% 44
2025
Q2 		$1.91M Buy
10,304
+377
+4% +$70.1K 0.57% 59
2025
Q1 		$2.08M Buy
9,927
+953
+11% +$185K 0.76% 44
2024
Q4 		$1.59M Buy
8,974
+131
+1% +$24.1K 0.57% 62
2024
Q3 		$1.75M Buy
8,843
+863
+11% +$161K 0.64% 55
2024
Q2 		$1.37M Sell
7,980
-1,442
-15% -$239K 0.57% 69
2024
Q1 		$1.72M Buy
9,422
+7,546
+402% +$1.3M 0.75% 54
2023
Q4 		$291K Buy
+1,876
New +$274K 0.14% 101
2022
Q2 		– Sell
-363
Closed -$59K – 102
2022
Q1 		$59K Buy
363
+255
+236% +$37K 0.04% 134
2021
Q4 		$15K Sell
108
-25
-19% -$2.95K 0.01% 179
2021
Q3 		$14K Hold
133
– – 0.01% 173
2021
Q2 		$15K Buy
+133
New +$15K 0.01% 169

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Alaethes Wealth's ABBV Position: Q2 2026 in Review

Alaethes Wealth increased its AbbVie (ABBV) stake by 12% in Q2 2026, buying an estimated $252K and bringing the position to 10,922 shares worth $2.75M. The position accounts for 0.8% of the portfolio, ranked #36.

Alaethes Wealth first reported a position in ABBV in Q2 2021 and has held it in 15 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Alaethes Wealth held 10,922 shares of AbbVie worth $2.75M as of Q2 2026.
  • Alaethes Wealth bought 1,173 AbbVie shares in Q2 2026, an estimated $252K.
  • AbbVie made up 0.8% of Alaethes Wealth's portfolio in Q2 2026, its #36 holding.
  • Alaethes Wealth first reported a position in AbbVie in Q2 2021 and has held it in 15 quarters since.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Alaethes Wealth's 13F filing for Q2 2026, filed 14 Aug 2026.